What Agent Should be Used to Prevent Recurrent Preterm Birth: 17-P or Natural Progesterone?

Obstetrics and Gynecology Clinics of North America

Volumn 38, Issue 2, 2011, Pages 235-246

  Hall, Nicole Ruddock ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

17 alpha hydroxyprogesterone caproate; Natural progesterone; Preterm birth; Prevention

Indexed keywords

CORTICOSTEROID; GESTAGEN; HYDROXYPROGESTERONE; HYDROXYPROGESTERONE CAPROATE; INTERLEUKIN 6; PLACEBO; PROGESTERONE; SURFACTANT;

CARDIOVASCULAR RISK; CEREBRAL PALSY; CONCENTRATION RESPONSE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; HEALTH CARE COST; HUMAN; IMMINENT ABORTION; IMMUNOREGULATION; MENTAL DEFICIENCY; MYOMETRIUM; NEWBORN MORBIDITY; NEWBORN MORTALITY; NONHUMAN; PREMATURE LABOR; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; RISK FACTOR; TOCOLYSIS; UTERINE CERVIX RIPENING; VISUAL IMPAIRMENT;

FEMALE; HUMANS; HYDROXYPROGESTERONES; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS; PREMATURE BIRTH; PROGESTERONE; PROGESTINS; RECURRENCE; TREATMENT OUTCOME;

EID: 79955945619     PISSN: 08898545     EISSN: 15580474     Source Type: Journal    
DOI: 10.1016/j.ogc.2011.02.014     Document Type: Review

References (66)

1. Goldenberg R.L., Culhane J.F., Iams J.D., et al. Epidemiology and causes of preterm birth. Lancet 2008, 371:75-84.
2. Spong C.Y. Prediction and prevention of recurrent spontaneous preterm birth. Obstet Gynecol 2007, 110(2 Pt 1):405-415.
3. 2000 Nationwide inpatient sample prepared by March of Dimes Perinatal Data Center 2003, Agency for Healthcare Research and Quality.
4. Salafia C.M., Vogel C.A., Vintzileos A.M., et al. Placental pathologic findings in preterm birth. Am J Obstet Gynecol 1991, 165(4 Pt 1):934-938.
5. Bhattacharya S., Raja E.A., Mirazo E.R., et al. Inherited predisposition to spontaneous preterm delivery. Obstet Gynecol 2010, 115(6):1125-1133.
6. Kiely J.L. What is the population-based risk of preterm birth among twins and other multiples?. Clin Obstet Gynecol 1998, 41(1):3-11.
7. Bryant A.S., Worjoloh A., Caughey A.B., et al. Racial/ethnic disparities in obstetric outcomes and care: prevalence and determinants. Am J Obstet Gynecol 2010, 202(4):335-343.
8. Bloom S.L., Yost N.P., McIntire D.D., et al. Recurrence of preterm birth in singleton and twin pregnancies. Obstet Gynecol 2001, 98(3):379-385.
9. Meis P.J., Klebanoff M., Thom E., et al. Prevention of recurrent preterm delivery by 17-alpha-hydroxyprogesterone caproate. N Engl J Med 2003, 348:2379-2385.
10. da Fonseca E.B., Bittar R.E., Carvalho M.H., et al. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double blind study. Am J Obstet Gynecol 2003, 188:419-424.
11. Siiteri P.K., Seron-Ferre M. Some new thoughts on the feto-placental unit and parturition in primates. Fetal endocrinology 1981, Academic Press, New York. J.M. Novy, A.J. Reskko (Eds.).
12. Garfield R.E., Dannan M.S., Daniel E.E. Gap junction formation in myometrium: control by estrogens, progesterone, and prostaglandins. Am J Physiol 1980, 238:C81-C89.
13. Csapo A.I. Force of labor 1981, John Wiley and Sons, New York, p. 761-99.
14. Chwalisz K., Hegele-Hartung C., Schulz R., et al. Progesterone control of cervical ripening 1991, Perinatology Press, p. 119-31.
15. Bernal A. Overview. Preterm labour: mechanisms and management. BMC Pregnancy Childbirth 2007, 7(Suppl 1):S2.
16. Zakar T., Hertelendy F. Progesterone withdrawal: key to parturition. Am J Obstet Gynecol 2007, 196(4):289-296.
17. Merlino A.A., Welsh T.N., Tan H., et al. Nuclear progesterone receptors in the human pregnancy myometrium: evidence that parturition involves functional progesterone withdrawal mediated by increased expression of progesterone receptor-A. J Clin Endocrinol Metab 2007, 92(5):1927-1933.
18. Petrocelli T., Lye S.J. Regulation of transcripts encoding the myometrial gap junction protein, connexin-43, by estrogen and progesterone. Endocrinology 1993, 133:284.
19. Clark K., Ji H., Feltovich H., et al. Mifepristone-induced cervical ripening: structural, biomechanical, and molecular events. Am J Obstet Gynecol 2006, 194:1391-1398.
20. Marx S.G., Wentz M.J., Mackay L.B., et al. Effects of progesterone on iNOS, COX-2, and collagen expression in the cervix. J Histochem Cytochem 2006, 54:623-639.
21. Shi L., Shi S.Q., Saade G.R., et al. Studies of cervical ripening in pregnant rats: effects of various treatments. Mol Hum Reprod 2000, 6:382-389.
22. Shynlova O., Mitchell J.A., Tsampalieros A., et al. Progesterone and gravidity differentially regulate expression of extracellular matrix components in the pregnant rat myometrium. Biol Reprod 2004, 70:986-992.
23. Melendez J.A., Vinci J.M., Jeffrey J.J., et al. Localization and regulation of IL-1alpha in rat myometrium during late pregnancy and the postpartum period. Am J Physiol Regul Integr Comp Physiol 2001, 280(3):R879-R888.
24. Suarez V.R., Park E.S., Hankins G.D., et al. Expression of regulator of G protein signaling-2 in rat myometrium during pregnancy and parturition. Am J Obstet Gynecol 2003, 188(4):973-977.
25. Elovitz M.A., Mrinalini C. Can medroxyprogesterone acetate alter Toll-like receptor expression in a mouse model of intrauterine inflammation?. Am J Obstet Gynecol 2005, 193(3 Pt 2):1149-1155.
26. Inglis S.R., Jeremias J., Kuno K., et al. Detection of tumor necrosis factor-alpha, interleukin-6, and fetal fibronectin in the lower genital tract during pregnancy: relation to outcome. Am J Obstet Gynecol 1994, 171:5-10.
27. Coleman M.A., Keelen J.A., McCowen L.M. Predicting preterm delivery: comparison of cervicovaginal interleukins (IL)-1beta, IL-6 and IL-8 with fetal fibronectin and cervical dilation. Eur J Obstet Gynecol Reprod Biol 2001, 95:154-158.
28. Rizzo G., Capponi A., Rinaldo D., et al. Interleukin-6 concentrations in cervical secretions identify microbial invasion of the amniotic fluid cavity in patients with preterm labor and intact membranes. Am J Obstet Gynecol 1996, 175:812-817.
29. Hauth J.C., Andrews W.W., Goldenberg R.L. Infection-related risk factors predictive of spontaneous preterm labor and birth. Prenat Neonatal Med 1983, 88:233-238.
30. Goldenberg R.L., Klebanoff M., Carey J.C., et al. Vaginal fetal fibronectin measurements from 8 to 22 weeks' gestation and subsequent spontaneous preterm birth. Am J Obstet Gynecol 2000, 183:469-475.
31. Keirse M.J. Progesterone administration in pregnancy may prevent preterm delivery. Br J Obstet Gynaecol 1990, 97:149-154.
32. Papaiernik E. Double-blind study of an agent to prevent pre-term delivery among women at increased risk. In: Edition Schering, Serie IV, fiche 3; 1970. p. 65-68.
33. Johnson J.W., Austin K.L., Jones G.S., et al. Efficacy of 17 alpha-hydroxyprogesterone caproate in the prevention of premature labor. N Engl J Med 1975, 293:675-680.
34. Levine L. Habitual abortion: a controlled clinical study of progestational therapy. West J Surg Obstet Gynecol 1964, 72:30-36.
35. Yemini M., Borenstein R., Dreazen E., et al. Prevention of premature labor by 17 alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol 1985, 151:574-577. p. 28-31.
36. American College of Obstetricians and Gynecologists Use of progesterone to reduce preterm birth: ACOG committee opinion, no 291. Obstet Gynecol 2003, 102:1115-1116.
37. Rouse D.J., Caritis S.N., Peaceman A.M., et al. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med 2007, 357:454-461.
38. Caritis S.N., Rouse D.J., Peaceman A.M., et al. Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial. Obstet Gynecol 2009, 113(2 Pt 1):285-292.
39. Fonseca E.B., Celik E., Parra M., et al. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 2007, 357:462-469.
40. Gyetvai K., Hannah M.E., Hodnett E.D., et al. Tocolytics for preterm labor: a systematic review. Obstet Gynecol 1999, 94:869-877.
41. Facchinetti F., Paganelli S., Comitini G., et al. Cervical length changes during preterm cervical ripening: effects of 17-alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol 2007, 196:453.e1-453.e4.
42. McPheeters M., Miller W., Hartmann K., et al. The epidemiology of threatened preterm labor: a prospective cohort study. Am J Obstet Gynecol 2005, 192:1329-1330.
43. De Ziegler D., Bulletti C., De Monstier B., et al. The first uterine pass effect. Ann N Y Acad Sci 1997, 828:291-299.
44. Cicinelli E., De Ziegler D., Bulletti C., et al. Direct transport of progesterone from vagina to uterus. Obstet Gynecol 2000, 95:403-406.
45. O'Brien J.M., Defranco E.A., Adair C.D., et al. Progesterone Vaginal Gel Study Group. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007, 34(6):653-659.
46. Hassan S.S., Romero R., Vidyadhari D., et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound in Obstetrics & Gynecology 2011, in press.
47. Borna S., Sahabi N. Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Aust N Z J Obstet Gynaecol 2008, 48(1):58-63.
48. Sherman A.I. Hormonal therapy for control of the incompetent os of pregnancy. Obstet Gynecol 1966, 28:198-205.
49. Kessler W., Borman A. Some biological activities of certain progesterons. I. 17 alpha-hydroxyprogesterone 17-n-caproate. Ann N Y Acad Sci 1958, 71:486-493.
50. Johnstone E.E., Franklin R.R. Assay of progestins for fetal virilizing properties using the mouse. Obstet Gynecol 1964, 23:359-362.
51. Courtney K.D., Valerio D.A. Teratology in the Macaca mulatta. Teratology 1968, 1:163-172.
52. Carbone J.P., Brent R.L. Genital and nongenital teratogenesis of prenatal progesterone therapy: the effects of 17 alpha-hydroxyprogesterone caproate on embryonic and fetal development and endochondral ossification in the C57B1/6L mouse. Am J Obstet Gynecol 1993, 169:1292-1298.
53. Junkmann K. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 1953, 220(5):358-364. [in Undetermined Language].
54. Suchowsky G.K., Junkmann K. Acta Endocrinol (Copenh) 1958, 28(2):129-131. [in German].
55. Seegmiller R.E., Nelson G.W., Johnston C.K. Evaluation of teratogenic potential of delalutin, (17 alpha-hydroxyprogesterone caproate) in mice. Teratology 1983, 28:201-208.
56. Varma T., Morsman J. Evaluation of the use of Proluton-Depot (hydroxyprogesterone hexanoate) in early pregnancy. Int J Gynaecol Obstet 1982, 20:13-17.
57. Michaelis J., Michaelis H., Gluck E., et al. Prospective studies of suspected association between certain drugs administered in early pregnancy and congenital malformations. Teratology 1983, 27:57-64.
58. Resseguie L.J., Hick J.F., Bruen J.A., et al. Congenital malformations among offspring exposed in utero to progestins. Olmstead County, Minnesota, 1936-1974. Fertil Steril 1985, 43:514-519.
59. Kesler P.A. Effects of prenatally administered 17 alpha-hydroxyprogesterone caproate in adolescent males. Arch Sex Behav 1984, 13:441-455.
60. Schardein J.L. Congenital abnormalities and hormones during pregnancy: a clinical review. Teratology 1980, 22:251-270.
61. Raman-Wilms L., Tseng A.L., Wighardt S., et al. Fetal genital effects of first-trimester sex hormone exposure: a meta-analysis. Obstet Gynecol 1995, 85:141-149.
62. Zhang S., Mada S.R., Sharma S., et al. Simultaneous quantitation of 17alpha-hydroxyprogesterone caproate, 17alpha-hydroxyprogesterone and progesterone in human plasma using high-performance liquid chromatography-mass spectrometry (HPLC-MS/MS). J Pharm Biomed Anal 2008, 48(4):1174-1180.
63. Sharma S., Ellis E.C., Dorko K., et al. Metabolism of 17alpha-hydroxyprogesterone caproate, an agent for preventing preterm birth, by fetal hepatocytes. Drug Metab Dispos 2010, 38(5):723-727.
64. Attardi Barbara J., Zeleznik Anthony, Simhan Hyagriv, et al. Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate (17-OHPC), and related progestins. Am J Obstet Gynecol 2007, 197(6):599.e1-599.e7.
65. Bailit J.L., Votruba M.E. Medical cost savings associated with 17 alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol 2007, 196(3):219.
66. Odibo A.O., Stamilio D.M., Macones G.A., et al. 17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: a cost-effectiveness analysis. Obstet Gynecol 2006, 108(3 Pt 1):492-499.